At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 9, 2026 at 06:59 ET
C4 Therapeutics announced a collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology targets, with an option for a third. C4T receives a $20 million upfront payment and is eligible for over $1 billion in potential milestone payments and future royalties.
- C4 Therapeutics entered a collaboration with Roche to develop degrader-antibody conjugates (DACs) for oncology targets.
- C4T will receive $20 million upfront and is eligible for over $1 billion in discovery, development, and commercial milestone payments.
- Roche will handle conjugation, preclinical/clinical development, and commercialization; C4T will design degrader payloads using its TORPEDO® platform.
- The deal includes tiered royalties on future sales, subject to reductions under certain circumstances.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access